Head of Investor Relations
About Parabilis Medicines
At Parabilis Medicines, we are redefining what's possible in drug discovery. We are a clinical-stage biopharmaceutical company dedicated to creating unique and extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered beyond the reach of conventional medicines. Our intent is to create an important long-lived company, partnering with the right investors at different points of our growth.
Our proprietary Helicon™ platform has pioneered a new class of stabilized alpha-helical peptides capable of modulating intracellular proteins that have historically been considered "undruggable." Our lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the β-catenin interaction that has demonstrated compelling early clinical activity across a range of Wnt/β-caten
